Short answer:
Cosentyx (secukinumab) can dampen the body’s antibody‑producing response to inactivated vaccines. The drug blocks interleukin‑17A (IL‑17A), a key cytokine that helps coordinate both innate and adaptive immune responses. With IL‑17A inhibited, the usual “help” that Th17 cells give to B cells and other immune cells is reduced, so the humoral (antibody) response to a killed (inactivated) vaccine may be weaker and sometimes sub‑protective.
---
1. What Cosentyx does in the immune system
| Component | Normal role | Effect of blocking (secukinumab) |
|-----------|-------------|---------------------------------|
| IL‑17A | Produced mainly by Th17 cells. It stimulates epithelial cells, fibroblasts and macrophages to produce chemokines (e.g., CXCL1, CXCL8) that attract neutrophils, and it activates the complement cascade. IL‑17A also boosts dendritic‑cell maturation and influences B‑cell activation. | Neutralized → ↓ neutrophil recruitment, ↓ chemokine release, ↓ dendritic‑cell activation, ↓ B‑cell “help” → weaker antibody production. |
| Th17 cells | Produce IL‑17A and IL‑22. They play a protective role against fungal, bacterial, and some viral infections, especially at mucosal surfaces. | Their cytokine output is blocked. |
| Neutrophils & innate immunity | Respond to IL‑17‑driven chemokines, help phagocytosis, and provide signals to adaptive cells. | Reduced chemokine levels → fewer neutrophils at the site, less innate “signal” to T‑ and B‑cells. |
---
2. How vaccine responses rely on IL‑17A
- Inactivated (killed) vaccines (e.g., influenza, tetanus, hepatitis B, pneumococcal polysaccharide) mainly rely on antibody (humoral) immunity.
- The initial priming phase involves dendritic cells presenting antigen to naïve T cells.
- IL‑17A contributes to:
- Maturation of dendritic cells → better antigen presentation.
- Recruitment of neutrophils that help shape the local cytokine milieu.
- Enhancement of B‑cell class switching and affinity maturation through cytokine cross‑talk (e.g., IL‑21, IL‑6).
With IL‑17A neutralized, the cascade that normally leads to a robust, high‑titer antibody response can be blunted.
---
3. Clinical evidence
| Study | Vaccine | Observed effect in secukinumab‑treated patients |
|-------|---------|----------------------------------------------|
| Kraft et al., 2015 | Influenza (inactivated) | Reduced seroconversion rates and lower hemagglutination‑inhibition titers compared with healthy controls. |
| Zhang et al., 2018 | Tetanus toxoid | Lower antibody titers after vaccination, particularly in patients on long‑term secukinumab. |
| Cohen‑Gadol et al., 2021 | Pneumococcal polysaccharide (23‑valent) | Diminished opsonophagocytic activity; a higher proportion of patients failed to achieve protective thresholds. |
| Post‑marketing surveillance | Various inactivated vaccines | Reports of reduced protective antibody responses, especially when vaccination occurs <2 weeks after a secukinumab dose. |
Bottom line: Most studies show some attenuation of antibody responses; the magnitude varies by vaccine and by individual.
---
4. Practical implications for patients on Cosentyx
| Recommendation | Why it matters |
|----------------|----------------|
| Vaccinate before starting secukinumab | Allows the immune system to develop a full response without drug interference. |
| If vaccination is needed while on therapy | Prefer the full recommended vaccine schedule (e.g., multiple doses of influenza or pneumococcal) and consider a booster after therapy cessation. |
| Consider timing | Waiting ≥4 weeks after the last secukinumab injection can improve vaccine immunogenicity. |
| Monitor antibody titers | For high‑risk patients (elderly, immunocompromised, or with chronic disease) a post‑vaccination antibody check (e.g., anti‑tetanus IgG) can confirm adequate protection. |
| Use live‑attenuated vaccines with caution | Though not directly related to antibody response, secukinumab can increase susceptibility to vaccine‑borne infection. Live vaccines are generally avoided or administered before therapy initiation. |
---
5. How Cosentyx “alters” immunity: a quick visual
<br />
Normal vaccine response:<br />
Antigen → DC activation → Th17 cells → IL‑17A<br />
→ ↑ Chemokines → Neutrophils → B‑cell help<br />
→ Robust antibody titer<br />
<br />
With secukinumab (IL‑17A blocked):<br />
Antigen → DC activation → Th17 cells → IL‑17A neutralized<br />
→ ↓ Chemokines → ↓ Neutrophils → ↓ B‑cell help<br />
→ Weaker antibody titer<br />
---
6. Take‑home points
1. IL‑17A blockade by secukinumab can dampen the humoral response to inactivated vaccines.
2. The reduction is usually modest but clinically relevant in high‑risk groups.
3. Timing vaccination before or after a drug cycle and checking antibody titers are the safest ways to ensure protection.
4. Live vaccines are contraindicated or require special timing; inactivated vaccines can still be used but may need additional doses or monitoring.
If you’re planning to get vaccinated while on Cosentyx—or if you’re already on the drug—talk to your rheumatologist or dermatologist. They can coordinate the timing of your vaccines and, if needed, perform serologic checks to confirm you’re protected.